Pablo J. Cagnoni

Insider Reports History

Location
South San Francisco, CA
Signature
/s/ Elizabeth Feeney, Attorney-In-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Pablo J. Cagnoni:

Form 4 holding President, Global Head of R&D

INCYTE CORP

Security class
Common Stock
Shares / value
262,692
Estimated value
$25,349,778
Report date
17 Apr 2026
Price
$96.50
Ownership
Direct
Form 4 holding Director

Rubius Therapeutics, Inc.

Security class
Restricted Stock Units
Shares / value
75,000
Estimated value
Report date
31 Jan 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President, Global Head of R&D

INCYTE CORP

Security class
Performance Shares
Shares / value
43,846
Estimated value
Report date
15 Jul 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President, Global Head of R&D

INCYTE CORP

Security class
Employee Stock Option (right to buy)
Shares / value
27,699
Estimated value
Report date
17 Apr 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Fusion Pharmaceuticals Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
04 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Pablo J. Cagnoni

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .